Continuation of Anti-TNF for IBD After 24 Weeks of Pregnancy Beneficial
Risk for maternal IBD relapse and prematurity reduced with continuation of anti-TNF after 24 weeks of pregnancy
Risk for maternal IBD relapse and prematurity reduced with continuation of anti-TNF after 24 weeks of pregnancy
A team of researchers investigated the association between postoperative recurrence of Crohn disease and a patient’s sex and race and ethnicity.
Researchers evaluated the effects of antibiotic exposure, specifically cumulative use, timing of use, and the association with older-onset IBD.
Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.
Investigators assessed trends in corticosteroid use in patients with IBD over a period of 20 years.
Current research indicates that short-term utilization of an LFD may help ameliorate some mild IBS symptoms associated with quiescent IBD, while further long term studies are still needed.
More research and follow-up on infliximab is needed to determine the appropriate length of treatment and who will benefit most from treatment.
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.